<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium benzoate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium benzoate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium benzoate: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_pediatric" data-topicid="12794" href="/d/html/12794.html" rel="external">see "Sodium benzoate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52576965"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ammonium Detoxicant;</li>
<li>
                        Hyperammonemia Agent;</li>
<li>
                        Urea Cycle Disorder (UCD) Treatment Agent</li></ul></div>
<div class="block doa drugH1Div" id="F52576971"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Sodium benzoate is not commercially available as a ready-to-use product; however, some centers are still using compounded formulations when necessary. IV dosing is usually required for acute episodes; if IV administration is necessary, see the Sodium Phenylacetate and Sodium Benzoate monograph for information about a commercially available parenteral product.</p></div>
<div class="block dora drugH1Div" id="F52576972"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosing information not available; use with caution.</p></div>
<div class="block doha drugH1Div" id="F52576973"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Dosing information not available; use with caution.</p></div>
<div class="block dop drugH1Div" id="F52812596"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12794" href="/d/html/12794.html" rel="external">see "Sodium benzoate: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Sodium benzoate is not commercially available as a ready-to-use product; however, some centers are still using compounded formulations when necessary. IV dosing is usually required for acute episodes; if IV administration is necessary, see the Sodium Phenylacetate and Sodium Benzoate monograph for information about a commercially available parenteral product.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70804394-9d44-47ad-90ec-7e1dbcd383a8">Urea cycle disorders, long-term therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urea cycle disorders, long-term therapy:</b> Very limited data available: Dosage should be individualized based on patient response; consult metabolic specialist:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: ≤250 mg/kg/day in 3 to 4 divided doses administered with meals as part of an appropriate combination therapy; maximum daily dose: 12 <b>g</b>/<b>day</b> (Häberle 2019; Maestri 1991; Maestri 1996). <b>Note: </b>Higher doses may be required in some patients (Häberle 2019) in consultation with a metabolic specialist.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729834"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;">Dosing information not available; use with caution.</p></div>
<div class="block dohp drugH1Div" id="F52729835"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Dosing information not available; use with caution.</p></div>
<div class="block adr drugH1Div" id="F247193"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Adverse reactions are from multiple indications and dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: ECG abnormality (Sushma 1992)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia (Wolff 1986), dyspepsia (Sushma 1992), epigastric distress (Sushma 1992), gastritis (Häberle 2012), mucositis (Häberle 2012), nausea (Sushma 1992), vomiting (Sushma 1992; Wolff 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypokalemia (Häberle 2012), increased serum sodium (Sushma 1992), metabolic acidosis (Häberle 2012)</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Renal tubular disease (Wolff 1986)</p></div>
<div class="block war drugH1Div" id="F247191"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid overload: Use with caution, if at all, in patients at risk for fluid overload (eg, heart failure, severe renal impairment) or sodium retention; contains a significant amount of sodium (Häberle 2019; Misel 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Acidemia: Use with caution in patients with propionic or methylmalonic acidemia (Kliegman 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Reye syndrome: Use with caution in patients with Reye syndrome (Kliegman 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Use with caution in neonates with hyperbilirubinemia due to potential displacement of bilirubin from albumin binding sites (Kliegman 2016).</p></div>
<div class="block foc drugH1Div" id="F52679247"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Powder: 454 g</p></div>
<div class="block adm drugH1Div" id="F52576975"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals and abundant fluid (Häberle 2012). Not commercially available; must be compounded using chemical powder; consult metabolic specialist.</p></div>
<div class="block admp drugH1Div" id="F52614114"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals/feeds and fluid to minimize gastritis/mucositis (Häberle 2019; Maines 2020). Not commercially available; must be compounded using chemical powder; consult metabolic specialist.</p></div>
<div class="block use drugH1Div" id="F247198"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Urea cycle disorders:</b> Adjunctive therapy for the prevention and treatment of hyperammonemia due to suspected or proven urea cycle disorders</p></div>
<div class="block cyt drugH1Div" id="F13300050"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222963"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: May diminish the therapeutic effect of Sodium Benzoate.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F52576966"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Benzoate can be detected in the umbilical cord and newborn serum following maternal administration of sodium benzoate prior to delivery (Das 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of sodium benzoate for urea cycle disorders (UCD), including ornithine transcarbamylase (OTC) deficiency, during pregnancy is limited (Häberle 2012; Lamb 2013; Mendez-Figueroa 2010). Pregnancy is a high metabolic state that can trigger hyperamonemic episodes in females with known OTC deficiency as well as asymptomatic female carriers; close monitoring is recommended during pregnancy and for 5 days postpartum (Arn 1990; Häberle 2012; Mendez-Figueroa 2010). Maternal treatment with oral sodium benzoate is recommended if serum ammonia is 1.5 to 2 times normal (Mendez-Figueroa 2010). Administration of sodium benzoate to the mother to prevent adverse events in newborns prenatally diagnosed with a UCD has also been described (Das 2009). In general, females with inherited metabolic disease should achieve adequate metabolic control prior to conception (Häberle 2012; Langendonk 2012).</p></div>
<div class="block brc drugH1Div" id="F52576967"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if sodium benzoate is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, females with inherited metabolic disease should ensure adequate energy intake if breastfeeding (Häberle 2012; Langendonk 2012). Breastfed infants with urea cycle disorders require close protein monitoring (Häberle 2012).</p></div>
<div class="block dic drugH1Div" id="F56777504"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Sodium benzoate contains ~81 mg (~3.5 mmol) of sodium per 500 mg of sodium benzoate (Häberle 2019; Misel 2013). Dietary protein restriction should be part of treatment of urea cycle disorders. Caloric supplementation (goal ≥80 kcal/kg/day) is recommended for patients in a catabolic state (NORD 2013).</p></div>
<div class="block mop drugH1Div" id="F247195"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma ammonia, plasma amino acid (quantitative) and glutamine concentrations, blood glucose, serum electrolytes, hepatic and renal function tests, blood gases, neurologic status, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment) (Häberle 2012; Lichter-Konecki 2016).</p></div>
<div class="block pha drugH1Div" id="F247189"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Assists in lowering serum ammonia levels by activation of a nonurea cycle pathway (the benzoate-hippurate pathway); ammonia in the presence of benzoate will conjugate with glycine to form hippurate which is excreted by the kidney</p></div>
<div class="block phk drugH1Div" id="F247200"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 0.75 to 7.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance is largely attributable to metabolism with urinary excretion of hippurate, the major metabolite</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F52765559"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Amzoate</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Natrium benzoat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amzoate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amzoate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-2342525">
<a name="2342525"></a>Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamoyltransferase locus. A cause of postpartum coma. <i>N Engl J Med</i>. 1990;322(23):1652-1655.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/2342525/pubmed" id="2342525" target="_blank">2342525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30021187">
<a name="30021187"></a>Atkins JR, Lull ME, Decker AS, Hutchinson DJ. Stability of extemporaneously prepared sodium benzoate oral suspension. <i>Int J Pharm Compd</i>. 2018;22(4):326-328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/30021187/pubmed" id="30021187" target="_blank">30021187</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  British Inherited Metabolic Disease Group (BIMDG). Management of a baby at risk of a urea cycle disorder at birth. https://www.bimdg.org.uk/store/guidelines/UCD-at-birthrev51-288975-22-05-2013.pdf. Reviewed April 2017a. Accessed March 17, 2023.</div>
</li>
<li>
<div class="reference">
                  British Inherited Metabolic Disease Group (BIMDG). Medicines used for the treatment of hyperammonaemia. https://www.bimdg.org.uk/store/guidelines/UCD-medicines2-330009-22-05-2013.pdf. Reviewed April 2017b. Accessed March 17, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19000997">
<a name="19000997"></a>Das AM, Illsinger S, Hartmann H, Oehler K, Bohnhorst B, Kühn-Velten WN, Lücke T. Prenatal benzoate treatment in urea cycle defects. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2009;94(3):216-217.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/19000997/pubmed" id="19000997" target="_blank">19000997</a>]</span>
<span class="doi">10.1136/adc.2008.144824</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22642880">
<a name="22642880"></a>Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. <i>Orphanet J Rare Dis</i>. 2012;7:32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/22642880/pubmed" id="22642880" target="_blank">22642880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982989">
<a name="30982989"></a>Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision.<i> J Inherit Metab Dis</i>. 2019;42(6):1192-1230. doi:10.1002/jimd.12100<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/30982989/pubmed" id="30982989" target="_blank">30982989</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23283608">
<a name="23283608"></a>Lamb S, Aye CY, Murphy E, Mackillop L. Multidisciplinary management of ornithine transcarbamylase (OTC) deficiency in pregnancy: essential to prevent hyperammonemic complications. <i>BMJ Case Rep</i>. 2013 Jan 2;2013. pii: bcr2012007416.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/23283608/pubmed" id="23283608" target="_blank">23283608</a>]</span>
<span class="doi">10.1136/bcr-2012-007416</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21918856">
<a name="21918856"></a>Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. <i>J Inherit Metab Dis</i>. 2012;35(3):419-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/21918856/pubmed" id="21918856" target="_blank">21918856</a>]</span>
<span class="doi">10.1007/s10545-011-9389-2</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24006547">
<a name="24006547"></a>Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. Ornithine transcarbamylase deficiency. 2013 Aug 29 [updated 2016 Apr 14]. In: Adam MP, Ardinger HH, Pagon RA, et al. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from <a href="http://www.ncbi.nlm.nih.gov/books/NBK154378/%20" target="_blank">http://www.ncbi.nlm.nih.gov/books/NBK154378/ </a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/24006547/pubmed" id="24006547" target="_blank">24006547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8778603">
<a name="8778603"></a>Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. <i>N Engl J Med</i>. 1996;335(12):855-859.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/8778603/pubmed" id="8778603" target="_blank">8778603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1720458">
<a name="1720458"></a>Maestri NE, Hauser ER, Bartholomew D, et al. Prospective treatment of urea cycle disorders. <i>J Pediatr</i>. 1991;119(6):923-928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/1720458/pubmed" id="1720458" target="_blank">1720458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32152836">
<a name="32152836"></a>Maines E, Urru SAM, Burri E, et al. Formulation and clinical evaluation of sodium benzoate oral solution for the treatment of urea cycle disorders in pediatric patients. <i>AAPS PharmSciTech</i>. 2020;21(3):100. doi:10.1208/s12249-020-01642-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/32152836/pubmed" id="32152836" target="_blank">32152836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458665">
<a name="20458665"></a>Mendez-Figueroa H, Lamance K, Sutton VR, Aagaard-Tillery K, Van den Veyver I. Management of ornithine transcarbamylase deficiency in pregnancy. <i>Am J Perinatol</i>. 2010;27(10):775-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/20458665/pubmed" id="20458665" target="_blank">20458665</a>]</span>
<span class="doi">10.1055/s-0030-1254240</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24711766">
<a name="24711766"></a>Misel ML, Gish RG, Patton H, Mendler M. Sodium benzoate for treatment of hepatic encephalopathy. <i>Gastroenterol</i>
<i>Hepatol (N Y)</i>. 2013;9(4):219-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/24711766/pubmed" id="24711766" target="_blank">24711766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NORD.1">
<a name="NORD.1"></a>National Organization for Rare Disorders (NORD). Urea cycle disorders. https://rarediseases.org/physician-guide/urea-cycle-disorders/. Updated 2013. Accessed February 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1618465">
<a name="1618465"></a>Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. <i>Hepatology</i>. 1992;16(1):138-144.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/1618465/pubmed" id="1618465" target="_blank">1618465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3706242">
<a name="3706242"></a>Wolff JA, Kulovich S, Yu AL, Qiao CN, Nyhan WL. The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. <i>Am J Dis Child</i>. 1986;140(6):596-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-benzoate-drug-information/abstract-text/3706242/pubmed" id="3706242" target="_blank">3706242</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 120131 Version 32.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
